The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis.

ABSTRACT:

Background and aims

In this study of metabolic dysfunction-associated steatohepatitis (MASH)-related Child-Pugh A cirrhosis (MASH cirrhosis), we used the cholate challenge test to quantify baseline disease severity and the subsequent impact of resmetirom treatment.

Methods

Thirty-two subjects enrolled in the Phase 3 open-label MAESTRO-NAFLD-1 trial with MASH cirrhosis underwent baseline dual cholate shunt testing, and 25 had subsequent retesting at 28 and 48 weeks. Blood was sampled from 0 to 90 minutes, serum concentrations measured, and parameters of function (disease severity index [DSI]), portal-systemic shunting (SHUNT%), and clinical risk (RISK ACE) were calculated. Responders were defined by > 2-point decrease in DSI, stable subjects by a ΔDSI within ±2, and nonrespon

SUBMITTER: Alkhouri N 

PROVIDER: S-EPMC12547258 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature